Asia Pacific HIV Injection Market

Asia Pacific HIV Injection Market Size, Share & Trends Analysis Report By Distribution Channel (Hospital Pharmacy, Drugs Stores & Retail Pharmacies, and Others), By Country and Growth Forecast, 2023 - 2030

Report Id: KBV-21369 Publication Date: March-2024 Number of Pages: 97
Special Offering:
Industry Insights | Market Trends
Highest number of Tables | 24/7 Analyst Support

Analysis of Market Size & Trends

The Asia Pacific HIV Injection Market would witness market growth of 18.7% CAGR during the forecast period (2023-2030).

The China market dominated the Asia Pacific HIV Injection Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $172.7 Million by 2029. The Japan market is registering a CAGR of 17.9% during (2023 - 2030). Additionally, The India market would showcase a CAGR of 19.4% during (2023 - 2030).

HIV injections are an important treatment option for people living with HIV, offering several advantages over oral medications, including improved adherence, reduced risk of drug interactions, and potentially higher efficacy. In recent years, the market has expanded substantially, propelled by the escalating the prevalence of HIV/AIDS and the rising need for efficacious treatment alternatives.

Injectable HIV medications offer several advantages over oral medications, including improved adherence, reduced pill burden, and potentially better long-term outcomes. As a result, the demand for injectable HIV medications has been steadily increasing, driving growth in the market. Regarding the management of HIV/AIDS, patient adherence and preference are critical, and injectable treatments contribute significantly to resolving these concerns.

The demand in the Asia Pacific is likely to be influenced by the high number of people living with HIV in the region, as well as the efforts of governments and organizations to expand access to HIV prevention, testing, treatment, and care. According to a report by the Organisation for Economic Co-operation and Development (OECD), Asia ranks second in the prevalence of individuals living with HIV, behind only sub-Saharan Africa. These factors will, consequently, bolster the development of the regional market.

Free Valuable Insights: The Global HIV Injection Market is Predict to reach USD 2.8 Billion by 2030, at a CAGR of 17.6%

Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Drugs Stores & Retail Pharmacies, and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.

Need a report that reflects how COVID-19 has impacted this market and its growth? Download Free Sample Now

List of Key Companies Profiled

  • GlaxoSmithKline PLC (GSK)
  • Gilead Sciences, Inc.
  • ImmunityBio, Inc.
  • F.Hoffmann-La Roche Ltd.
  • Theratechnologies Inc.
  • Viriom, Inc.
  • AbbVie, Inc.
  • Brii Biosciences Limited
  • Shionogi & Co., Ltd.
  • Boehringer Ingelheim International GmbH

Asia Pacific HIV Injection Market Report Segmentation

By Distribution Channel

  • Hospital Pharmacy
  • Drugs Stores & Retail Pharmacies
  • Others

By Country

  • China
  • Japan
  • India
  • South Korea
  • Singapore
  • Malaysia
  • Rest of Asia Pacific
HAVE A QUESTION?

HAVE A QUESTION?

Call: +1(646) 600-5072

SPECIAL PRICING & DISCOUNTS


  • Buy Sections of This Report
  • Buy Country Level Reports
  • Request for Historical Data
  • Discounts Available for Start-Ups & Universities

Unique Offerings Unique Offerings


  • Exhaustive coverage
  • The highest number of Market tables and figures
  • Subscription-based model available
  • Guaranteed best price
  • Support with 10% customization free after sale

Trusted by over
5000+ clients

Our team of dedicated experts can provide you with attractive expansion opportunities for your business.

Client Logo